263 related articles for article (PubMed ID: 24808022)
21. Pharmaco-induced erections for penile color-duplex ultrasound: oral PDE5 inhibitors or intracavernosal injection?
Yang Y; Hu JL; Ma Y; Wang HX; Chen Z; Xia JG; Wang YX; Huang YR; Chen B
Int J Impot Res; 2012 Sep; 24(5):191-5. PubMed ID: 22592761
[TBL] [Abstract][Full Text] [Related]
22. Chronic treatment with the phosphodiesterase type 5 inhibitors sildenafil and tadalafil display anxiolytic effects in Flinders Sensitive Line rats.
Liebenberg N; Harvey BH; Brand L; Wegener G; Brink CB
Metab Brain Dis; 2012 Sep; 27(3):337-40. PubMed ID: 22359075
[TBL] [Abstract][Full Text] [Related]
23. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction.
Rubio-Aurioles E; Porst H; Kim ED; Montorsi F; Hackett G; Morales AM; Stuckey B; Būttner H; West TM; Huynh NN; Lenero E; Burns P; Kopernicky V
J Sex Med; 2012 May; 9(5):1418-29. PubMed ID: 22429760
[TBL] [Abstract][Full Text] [Related]
24. Functional sympatholysis is impaired in hypertensive humans.
Vongpatanasin W; Wang Z; Arbique D; Arbique G; Adams-Huet B; Mitchell JH; Victor RG; Thomas GD
J Physiol; 2011 Mar; 589(Pt 5):1209-20. PubMed ID: 21224235
[TBL] [Abstract][Full Text] [Related]
25. Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets.
Toque HA; Teixeira CE; Priviero FB; Morganti RP; Antunes E; De Nucci G
Br J Pharmacol; 2008 Jun; 154(4):787-96. PubMed ID: 18536732
[TBL] [Abstract][Full Text] [Related]
26. A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy.
Kim ED; Seftel AD; Goldfischer ER; Ni X; Burns PR
J Sex Med; 2014 Mar; 11(3):820-30. PubMed ID: 23841532
[TBL] [Abstract][Full Text] [Related]
27. Differential vasoactive effects of sildenafil and tadalafil on cerebral arteries.
Kruuse C; Gupta S; Nilsson E; Kruse L; Edvinsson L
Eur J Pharmacol; 2012 Jan; 674(2-3):345-51. PubMed ID: 22094063
[TBL] [Abstract][Full Text] [Related]
28. Nitric oxide-dependent attenuation of noradrenaline-induced vasoconstriction is impaired in the canine model of Duchenne muscular dystrophy.
Kodippili K; Hakim CH; Yang HT; Pan X; Yang NN; Laughlin MH; Terjung RL; Duan D
J Physiol; 2018 Nov; 596(21):5199-5216. PubMed ID: 30152022
[TBL] [Abstract][Full Text] [Related]
29. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G
J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626
[TBL] [Abstract][Full Text] [Related]
30. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
31. [Pharmacological treatment of pulmonary hypertension at a turning point].
Watanabe H
Nihon Yakurigaku Zasshi; 2014 Apr; 143(4):165-72. PubMed ID: 24717603
[No Abstract] [Full Text] [Related]
32. Role of neuronal nitric oxide synthase (nNOS) in Duchenne and Becker muscular dystrophies - Still a possible treatment modality?
Dombernowsky NW; Ölmestig JNE; Witting N; Kruuse C
Neuromuscul Disord; 2018 Nov; 28(11):914-926. PubMed ID: 30352768
[TBL] [Abstract][Full Text] [Related]
33. Antidepressant-like properties of phosphodiesterase type 5 inhibitors and cholinergic dependency in a genetic rat model of depression.
Liebenberg N; Harvey BH; Brand L; Brink CB
Behav Pharmacol; 2010 Sep; 21(5-6):540-7. PubMed ID: 20555254
[TBL] [Abstract][Full Text] [Related]
34. In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach.
Gratzke C; Uckert S; Kedia G; Reich O; Schlenker B; Seitz M; Becker AJ; Stief CG
Urol Res; 2007 Feb; 35(1):49-54. PubMed ID: 17102958
[TBL] [Abstract][Full Text] [Related]
35. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta.
Teixeira CE; Priviero FB; Webb RC
J Pharmacol Exp Ther; 2006 Feb; 316(2):654-61. PubMed ID: 16204472
[TBL] [Abstract][Full Text] [Related]
36. Influence of sildenafil on the anticonvulsant action of selected antiepileptic drugs against pentylenetetrazole-induced clonic seizures in mice.
Nieoczym D; Socała K; Łuszczki JJ; Czuczwar SJ; Wlaz P
J Neural Transm (Vienna); 2012 Aug; 119(8):923-31. PubMed ID: 22315091
[TBL] [Abstract][Full Text] [Related]
37. Pathways Implicated in Tadalafil Amelioration of Duchenne Muscular Dystrophy.
De Arcangelis V; Strimpakos G; Gabanella F; Corbi N; Luvisetto S; Magrelli A; Onori A; Passananti C; Pisani C; Rome S; Severini C; Naro F; Mattei E; Di Certo MG; Monaco L
J Cell Physiol; 2016 Jan; 231(1):224-32. PubMed ID: 26097015
[TBL] [Abstract][Full Text] [Related]
38. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension.
Sabri MR; Beheshtian E
Pediatr Cardiol; 2014 Apr; 35(4):699-704. PubMed ID: 24253611
[TBL] [Abstract][Full Text] [Related]
40. Sildenafil citrate in the treatment of pain in primary dysmenorrhea: a randomized controlled trial.
Dmitrovic R; Kunselman AR; Legro RS
Hum Reprod; 2013 Nov; 28(11):2958-65. PubMed ID: 23925396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
